Similarly, Acute myeloid leukemia (AML) blasts modified with IL-2/CD80 as a vaccine in vitro can induce peripheral blood mononuclear cells from AML patients to secrete higher levels of IFN-γand show stronger lytic activity against autologous, unmodified blasts (81). This evidence concerns the gene CD80 and acute myeloid leukemia.